Genetically diverse influenza antibodies highlight the role of IG germline gene variation and inform population-comprehensive vaccine strategies
Alexandra A. M. Fischer·Gunilla B. Karlsson Hedestam·Ioannis Zygouras·Martin Corcoran·Xaquín Castro Dopico·Sanjana Narang·Mark Chernyshev·Julianna Han·Masaru Kanekiyo·Pradeepa Pushparaj·Rebecca A. Gillespie·Alesandra J. Rodriguez·Andrew B. Ward·James A. Ferguson·Marit J. van Gils·Johannes R. Loeffler·Philip J.M. Brouwer·Andrea Nicoletto
The regular emergence of influenza strains with pandemic potential necessitates vaccines that elicit protective immune responses across genetically diverse human populations. A critical but understudied factor is how germline-encoded variation in immunoglobulin genes shapes the development of neutralizing antibodies. Here, by combining personalized immunoglobulin genotyping with high-throughput paired-chain antibody sequencing from influenza A hemagglutinin (HA)-binding B cells across four donor